Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 138

1.

Cannabidiol in the Treatment of Post-Traumatic Stress Disorder: A Case Series.

Elms L, Shannon S, Hughes S, Lewis N.

J Altern Complement Med. 2018 Dec 13. doi: 10.1089/acm.2018.0437. [Epub ahead of print]

PMID:
30543451
2.

Peripubertal cannabidiol treatment rescues behavioral and neurochemical abnormalities in the MAM model of schizophrenia.

Stark T, Ruda-Kucerova J, Iannotti FA, D'Addario C, Di Marco R, Pekarik V, Drazanova E, Piscitelli F, Bari M, Babinska Z, Giurdanella G, Di Bartolomeo M, Salomone S, Sulcova A, Maccarrone M, Wotjak CT, Starcuk Z Jr, Drago F, Mechoulam R, Di Marzo V, Micale V.

Neuropharmacology. 2018 Nov 26;146:212-221. doi: 10.1016/j.neuropharm.2018.11.035. [Epub ahead of print]

PMID:
30496751
3.

Neuroprotection by cannabidiol and hypothermia in a piglet model of newborn hypoxic-ischemic brain damage.

Barata L, Arruza L, Rodríguez MJ, Aleo E, Vierge E, Criado E, Sobrino E, Vargas C, Ceprián M, Gutiérrez-Rodríguez A, Hind W, Martínez-Orgado J.

Neuropharmacology. 2018 Nov 20;146:1-11. doi: 10.1016/j.neuropharm.2018.11.020. [Epub ahead of print]

PMID:
30468796
4.

Medical Use of Cannabinoids.

Fraguas-Sánchez AI, Torres-Suárez AI.

Drugs. 2018 Nov;78(16):1665-1703. doi: 10.1007/s40265-018-0996-1. Review.

PMID:
30374797
5.

Up-regulation of heme oxygenase-1 expression and inhibition of disease-associated features by cannabidiol in vascular smooth muscle cells.

Schwartz M, Böckmann S, Hinz B.

Oncotarget. 2018 Oct 2;9(77):34595-34616. doi: 10.18632/oncotarget.26191. eCollection 2018 Oct 2.

6.

Cannabidiol regulates the expression of hypothalamus-pituitary-adrenal axis-related genes in response to acute restraint stress.

Viudez-Martínez A, García-Gutiérrez MS, Manzanares J.

J Psychopharmacol. 2018 Dec;32(12):1379-1384. doi: 10.1177/0269881118805495. Epub 2018 Oct 16.

PMID:
30324842
7.

Translational Investigation of the Therapeutic Potential of Cannabidiol (CBD): Toward a New Age.

Crippa JA, Guimarães FS, Campos AC, Zuardi AW.

Front Immunol. 2018 Sep 21;9:2009. doi: 10.3389/fimmu.2018.02009. eCollection 2018. Review.

8.

Anti-stress neuropharmacological mechanisms and targets for addiction treatment: A translational framework.

Greenwald MK.

Neurobiol Stress. 2018 Aug 11;9:84-104. doi: 10.1016/j.ynstr.2018.08.003. eCollection 2018 Nov. Review.

9.

Cannabidiol prevents haloperidol-induced vacuos chewing movements and inflammatory changes in mice via PPARγ receptors.

Sonego AB, Prado DS, Vale GT, Sepulveda-Diaz JE, Cunha TM, Tirapelli CR, Del Bel EA, Raisman-Vozari R, Guimarães FS.

Brain Behav Immun. 2018 Nov;74:241-251. doi: 10.1016/j.bbi.2018.09.014. Epub 2018 Sep 11.

PMID:
30217539
10.

A Brief Background on Cannabis: From Plant to Medical Indications.

Klumpers LE, Thacker DL.

J AOAC Int. 2018 Aug 23. doi: 10.5740/jaoacint.18-0208. [Epub ahead of print]

PMID:
30139415
11.

Pharmacological Comparisons Between Cannabidiol and KLS-13019.

Brenneman DE, Petkanas D, Kinney WA.

J Mol Neurosci. 2018 Sep;66(1):121-134. doi: 10.1007/s12031-018-1154-7. Epub 2018 Aug 14.

PMID:
30109468
12.

Cannabidiol as a Therapeutic Alternative for Post-traumatic Stress Disorder: From Bench Research to Confirmation in Human Trials.

Bitencourt RM, Takahashi RN.

Front Neurosci. 2018 Jul 24;12:502. doi: 10.3389/fnins.2018.00502. eCollection 2018. Review.

13.

Cannabidiol restores differentiation capacity of LPS exposed adipose tissue mesenchymal stromal cells.

Ruhl T, Kim BS, Beier JP.

Exp Cell Res. 2018 Sep 15;370(2):653-662. doi: 10.1016/j.yexcr.2018.07.030. Epub 2018 Jul 20.

PMID:
30036540
14.

Hippocampal mammalian target of rapamycin is implicated in stress-coping behavior induced by cannabidiol in the forced swim test.

Sartim AG, Sales AJ, Guimarães FS, Joca SR.

J Psychopharmacol. 2018 Aug;32(8):922-931. doi: 10.1177/0269881118784877. Epub 2018 Jul 3.

PMID:
29968502
15.

Cannabidiol induced apoptosis in human monocytes through mitochondrial permeability transition pore-mediated ROS production.

Wu HY, Huang CH, Lin YH, Wang CC, Jan TR.

Free Radic Biol Med. 2018 Aug 20;124:311-318. doi: 10.1016/j.freeradbiomed.2018.06.023. Epub 2018 Jun 22.

PMID:
29940353
16.

Cannabidiol as a Promising Strategy to Treat and Prevent Movement Disorders?

Peres FF, Lima AC, Hallak JEC, Crippa JA, Silva RH, Abílio VC.

Front Pharmacol. 2018 May 11;9:482. doi: 10.3389/fphar.2018.00482. eCollection 2018. Review.

17.

A Model of Δ9-Tetrahydrocannabinol Self-administration and Reinstatement That Alters Synaptic Plasticity in Nucleus Accumbens.

Spencer S, Neuhofer D, Chioma VC, Garcia-Keller C, Schwartz DJ, Allen N, Scofield MD, Ortiz-Ithier T, Kalivas PW.

Biol Psychiatry. 2018 Oct 15;84(8):601-610. doi: 10.1016/j.biopsych.2018.04.016. Epub 2018 May 3.

PMID:
29861097
18.

Review of the neurological benefits of phytocannabinoids.

Maroon J, Bost J.

Surg Neurol Int. 2018 Apr 26;9:91. doi: 10.4103/sni.sni_45_18. eCollection 2018. Review.

19.

Unique treatment potential of cannabidiol for the prevention of relapse to drug use: preclinical proof of principle.

Gonzalez-Cuevas G, Martin-Fardon R, Kerr TM, Stouffer DG, Parsons LH, Hammell DC, Banks SL, Stinchcomb AL, Weiss F.

Neuropsychopharmacology. 2018 Sep;43(10):2036-2045. doi: 10.1038/s41386-018-0050-8. Epub 2018 Mar 22.

20.

A naturalistic examination of the perceived effects of cannabis on negative affect.

Cuttler C, Spradlin A, McLaughlin RJ.

J Affect Disord. 2018 Aug 1;235:198-205. doi: 10.1016/j.jad.2018.04.054. Epub 2018 Apr 6.

Supplemental Content

Loading ...
Support Center